Mahendra P. Deonarain

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs.

Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs.

Journal: Molecular cancer therapeutics

Published: December 18, 2024

Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy.

Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy.

Journal: Expert opinion on drug discovery

Published: December 04, 2020

Tackling solid tumour therapy with small-format drug conjugates.

Tackling solid tumour therapy with small-format drug conjugates.

Journal: Antibody therapeutics

Published: August 26, 2020

Miniaturised 'antibody'-drug conjugates for solid tumours?

Miniaturised 'antibody'-drug conjugates for solid tumours?

Journal: Drug discovery today. Technologies

Published: September 10, 2018

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Journal: Antibodies (Basel, Switzerland)

Published: February 16, 2018

Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.

Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.

Journal: Oncotarget

Published: January 29, 2018

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate.

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate.

Journal: Oncotarget

Published: August 11, 2016

A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.

A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.

Journal: Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology

Published: August 10, 2016

Emerging formats for next-generation antibody drug conjugates.

Emerging formats for next-generation antibody drug conjugates.

Journal: Expert opinion on drug discovery

Published: March 24, 2015

Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile.

Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile.

Journal: PloS one

Published: September 30, 2014

Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.

Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.

Journal: Breast cancer research and treatment

Published: August 26, 2014

Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin.

Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin.

Journal: Protein expression and purification

Published: October 11, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026